incretin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-23 and is reviewed periodically as new material appears.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
nondisjunction The failure of homologous chromosomes or sister chromatids to segregate properly during cell division. Nondisjunction results in daughter cells that are aneuploid, containing abnormal numbers of one or more specific chromosomes. It may be caused by a variety of factors.
According to Stéphane Quideau, the term "polyphenol" refers to compounds derived from the shikimate/phenylpropanoid and/or the polyketide pathway, featuring more than one phenolic unit and deprived of nitrogen-based functions. Ellagic acid, a molecule at the core of naturally occurring phenolic compounds of varying sizes, is itself not a polyphenol by the WBSSH definition, but is by the Quideau definition. The raspberry ellagitannin, on the other hand, with its 14 gallic acid moieties (most in ellagic acid-type components), and more than 40 phenolic hydroxyl groups, meets the criteria of both definitions of a polyphenol. Other examples of compounds that fall under both the WBSSH and Quideau definitions include the black tea theaflavin-3-gallate shown below, and the hydrolyzable tannin, tannic acid.
=== Subcellular localization === The c1orf27 protein is likely cytoplasmic. This was found with 55.5 reliability. The K-NN prediction was k = 9/23 and the protein was found to be 55.6% cytoplasmic, 11.1% mitochondrial, 11.1% vacuolar, 11.1% cytoskeletal, and 11.1% golgi.
A psychometric function with a log concentration–perceived intensity plot is characterised by its sigmoidal shape, with its initial baseline representing the compound at concentrations below its threshold, a slow rise in response around the inflection point representing the threshold, an exponential rise in response as the concentration exceeds the threshold, a deceleration of the response to a flat region as the zone of saturation or the point at which the change in intensity is no longer perceived is reached. On the other hand, a log concentration–log perceived intensity plot, using Steven's power law, forms a linear line with the exponent characterising the relationship between the two variables.
The M80 Stiletto is an American prototype naval ship using advanced stealth technologies. The M80 was designed by the M Ship Company then built by Knight and Carver, as an experimental testbed ship for The Pentagon’s Office of Force Transformation. It is notable for its innovative pentamaran hull design and advanced carbon fiber composite construction. The multihull uses its width to gain stability. Its five slim hulls create virtually no bow wave, thus obviating the "hull speed' limitation of displacement craft. The Stiletto's "double-M hull" enables the craft to achieve a remarkably steady ride in rough seas at high speed. A disadvantage is that the five hulls give a large "wetted area", increasing drag.
Sources: en.wikipedia.org
The Fourth Armoured Division, being an elite military unit permitted to move freely across Assad regime's checkpoints, oversees the smuggling operations from Syria, including the trafficking of cash, weapons, illegal drugs, etc. Days after the publication of the joint BBC-OCCRP documentary; Assad government banned all activities of BBC media outlets and entry of affiliated media personnel in Syria. The extensive involvement of Syrian Armed Forces in sponsorship of drug production and trade has led to pervasive drug addiction problems amongst pro-Assad soldiers. In many instances, military officials encourage the soldiers to consume Captagon and other illegal drugs, leading to overdose or drug abuse. Pro-Assad fighters in the National Defence Forces and Hezbollah also consume illegal drugs in large quantities. In July 2023, German police busted a major captagon network run by two Syrian-born men in southern German state of Bavaria. Assad regime sponsors the largest Captagon production network in Syria; which is the source of about 80% of total captagon supply in the world.
Divinylbenzene (DVB) is an organic compound with the chemical formula C6H4(CH=CH2)2 and structure H2C=CH−C6H4−HC=CH2 (a benzene ring with two vinyl groups as substituents). It is related to styrene (vinylbenzene, C6H5−CH=CH2) by the addition of a second vinyl group. It is a colorless liquid manufactured by the thermal dehydrogenation of isomeric diethylbenzenes. Under synthesis conditions, o-divinylbenzene converts to naphthalene and thus is not a component of the usual mixtures of DVB.
The authors concluded that the effects previously attributed to oxazepam were instead likely caused by a combination of fish being stressed by human handling and small aquaria, followed by being exposed to a novel environment.
Onyx Pharmaceuticals, Inc. was a pharmaceutical company headquartered in South San Francisco, California that developed and marketed cancer treatment medications. It was founded and incorporated with the California Secretary of State in February 1992 by venture capitalist Kevin J. Kinsella and Frank McCormick, Ph.D., FRS, D.Sc. (Hon.), a renowned British-American biochemist. McCormick served as the chief scientific officer until 1996, while Kinsella chaired the company's board of directors. On March 26, 1996, Onyx withdrew its corporate registration with the California Secretary of State and reincorporated in the state of Delaware in advance of successfully taking the company public on the NASDAQ exchange using National Market symbol ONXX on May 9, 1996. In 2009, the company acquired private biotechnology company Proteolix for US$276 million in cash plus additional milestone payments. In January 2012, the company was named "the top biotechnology takeover target in 2012" in an industry survey conducted by the ISI Group. Onyx president and CEO N. Anthony Coles had said that Onyx liked its prospects as an independent company and was focused on bringing new therapies to patients. However, by the end of August 2013, Amgen announced that it was acquiring Onyx in an agreed US$10.4 billion deal.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.